all report title image
  • Published On : Aug 2022
  • Code : CMI5185
  • Industry : Pharmaceutical
  • Pages : 156
  • Formats :

Disease-modifying antirheumatic drugs (DMARDs) are a group of medications commonly used in people with rheumatoid arthritis. Some of these drugs are also used in treating other conditions such as ankylosing spondylitis, psoriatic arthritis, and systemic lupus erythematosus. Disease-modifying antirheumatic drugs work to decrease pain and inflammation, to reduce or prevent joint damage, and to preserve the structure and function of the joints.

The global disease-modifying antirheumatic drug (DMARD) market is estimated to be valued at US$ 20,671.1 million in 2022 and is expected to exhibit a CAGR of 3.5% during the forecast period (2022-2030).

Figure 1.Global Disease-Modifying Antirheumatic Drug (DMARD) Market Share (%) in Terms of Value, By Drug Type, 2022

Disease-Modifying Antirheumatic Drug (DMARD)  | Coherent Market Insights

Increasing prevalence of rheumatoid arthritis disease is expected to drive the market growth during the forecast period.

Increasing prevalence of rheumatoid arthritis disease which is expected to drive the global disease-modifying antirheumatic drug (DMARD) market growth over the forecast period. For instance, according to data published by National Center for Biotechnology Information in June 2022, stated that the annual incidence of RA (Rheumatoid Arthritis) in the U.S. and other western nations of northern Europe is about 40 per 100,000 persons.

CMI table icon

Disease-Modifying Antirheumatic Drug (DMARD) Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 20,671.1 Mn
Historical Data for: 2017-2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 3.5% 2030 Value Projection: US$ 27,167.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Synthetic (sDMARD) (Conventional synthetic (csDMARDs) (Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine, Gold Salts)), Targeted synthetic DMARDs (tsDMARDs), Biological DMARDs (bDMARD) ( Original DMARDs (boDMARDs), Biosimilar DMARDs (bsDMARDs) (Primary, Secondary, Tertiary))), Others
  • By Route of Administration: Oral, Parenteral, Others
  • By Indication: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Systemic Lupus Erythematosus, Others
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Companies covered:

Sanofi.,  Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB,  Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc

Growth Drivers:
  • Increasing prevalence of rheumatoid arthritis disease
  • Increasing product launches for the treatment of rheumatoid arthritis, psoriasis, etc.
Restraints & Challenges:
  • Side effects associated with the  disease-modifying antirheumatic drug

Figure 2. Global Disease-Modifying Antirheumatic Drug (DMARD) Market Share (%), By Distribution Channel, 2022

Disease-Modifying Antirheumatic Drug (DMARD)  | Coherent Market Insights

Increasing product launches for the treatment of rheumatoid arthritis, psoriasis, etc., are expected to drive the market growth during the forecast period

Increasing product launches for the treatment of rheumatoid arthritis, psoriasis which is expected to drive the global disease-modifying antirheumatic drug (DMARD) market growth during the forecast period. For instance, in November 2020, Cumberland Pharmaceuticals Inc., a U.S. specialty pharmaceutical company, announced the launch of RediTrex injection. RediTrex is a new line of pre-filled syringes specifically designed for ease of handling and dosing accuracy for the subcutaneous administration of methotrexate in patients with rheumatoid arthritis and psoriasis.

Global Disease-Modifying Antirheumatic Drug (DMARD) Market– Impact of Coronavirus (COVID-19) Pandemic

The supply of raw materials required for production of pharmaceuticals has been severely disrupted due to the forced quarantine and lack of labor during the COVID-19 pandemic. As the link between regional warehouses is not smooth, transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components has negatively affected the supply chain of the global intraocular melanoma treatment market. Thus, COVID-19 pandemic is expected to have negative impact on supply chain of disease-modifying antirheumatic drug market. According to an article published by the Exploratory Research in Clinical and Social Pharmacy journal in June 2021, a study was carried out to evaluate the impact of COVID-19 on pharmaceutical systems and supply chain in resource-limited countries in Sub-Saharan countries such as Namibia. This study revealed negative impact on availability and access of essential drugs, sanitation and hygiene products, and antimicrobials. Most pharmaceutical companies and pharmacies in Namibia experienced delayed manufacturing and distribution of drugs, which is attributed to reduced inter-country transportation of pharmaceutical goods and limited in-country capacity to manufacture drugs. For instance, according to a review article published by the European Pharmaceutical Review journal in November 2020, COVID-19 pandemic has caused major challenges with respect to drug shortages and increased manufacturing costs across the globe. Moreover, the same source stated that COVID-19 pandemic has also led to problems such as stockpiling drugs, transportation delay, and others. Some measures that can be taken to ease the supply of pharmaceuticals during the pandemic include next generation technologies such as digital network platforms designed to work across multiple pharmaceutical enterprises and ensure the timely delivery of drugs to patients across the globe.

Global Disease-Modifying Antirheumatic Drug (DMARD) Market: Restraint

The major factors that hinder growth of the global disease-modifying antirheumatic drug (DMARD) market include side effects associated with the disease-modifying antirheumatic drug. Azathioprine (Imuran) is used for many different inflammatory conditions, including RA. The most common side effects are nausea and vomiting, sometimes with stomach pain and diarrhea. Long-term use of azathioprine is associated with an increased risk of cancer.

Key Players

Key players operating in the market include Sanofi.,  Pfizer,  F. Hoffman-La Roche AG,  Johnson & Johnson,  AbbVie Inc., Eli Lilly & Company,  Amgen Inc.,  Swedish Orphan Biovitrum AB,  Bristol-Myers Squibb Company,  UCB S.A.,  Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.

Disease-modifying anti-rheumatic drugs (DMARDs) can treat the underlying cause of condition and reduce inflammation. They are given to people with autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis and others. These are conditions where the immune system, which normally fights infection, attacks the body’s own healthy tissues. DMARDs can improve symptoms such as pain, stiffness and swelling, but they may take a few weeks or even months to fully take effect. There are different types of DMARDs, and they work in slightly different ways. The three main types are: synthetic (sDMARD), targeted synthetic DMARDs, biological DMARDs (bDMARD) and others

Market Dynamics

Key players operating in the global disease-modifying anti-rheumatic drugs (DMARDs) market are focusing on increasing product launches and product approvals which is expected to drive the market growth during the forecast period. For instance, in January 2018, Hetero, one of the leading generic pharmaceutical companies launched its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘Mabura’ in India.  Mabura is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF). It is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. Moreover, in September 2020, Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation announced that the U.S. Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.

 Key features of the study:

  • This report provides an in-depth analysis of the global disease-modifying anti-rheumatic drugs (DMARDs)  market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global disease-modifying anti-rheumatic drugs (DMARDs)  market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include Sanofi.,  Pfizer,  F. Hoffman-La Roche AG,  Johnson & Johnson,  AbbVie Inc., Eli Lilly & Company,  Amgen Inc.,  Swedish Orphan Biovitrum AB,  Bristol-Myers Squibb Company,  UCB S.A.,  Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global disease-modifying anti-rheumatic drugs (DMARDs) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global disease-modifying anti-rheumatic drugs (DMARDs) market

Detailed Segmentation:

  • Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Drug Type:
    • Synthetic (sDMARD)
      • Conventional synthetic (csDMARDs)
        • Methotrexate
        • Sulfasalazine
        • Leflunomide
        • Hydroxychloroquine
        • Gold Salts
    • Targeted synthetic DMARDs (tsDMARDs)
    • Biological DMARDs (bDMARD)
      • Original DMARDs (boDMARDs)
      • Biosimilar DMARDs (bsDMARDs)
      • Primary
      • Secondary
      • Tertiary
    • Others
  • Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Route of Administration  :
    • Oral
    • Parenteral
    • Others
  • Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Indication :
    • Rheumatoid Arthritis
      • Ankylosing Spondylitis
      • Psoriatic Arthritis
      • Systemic Lupus Erythematosus
      • Others
  • Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Distribution Channel  :
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Sanofi *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Pfizer.
    • F. Hoffman-La Roche AG
    •  Johnson & Johnson
    • AbbVie Inc.
    • Eli Lilly & Company
    • Amgen Inc.
    • Swedish Orphan Biovitrum AB
    • Bristol-Myers Squibb Company
    • UCB S.A.
    • Gilead Sciences, Inc.
    • Cumberland Pharmaceuticals Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The Global Disease-Modifying Antirheumatic Drug (DMARD) Market size is estimated to be valued at US$ 20,671.1 million in 2022 and is expected to exhibit a CAGR of 3.5% between 2022 and 2030
Factors such as increasing prevalence of rheumatoid arthritis disease and increasing product launches for the treatment of rheumatoid arthritis, psoriasis, etc., are expected to drive the market growth over forecast period
Synthetic (sDMARD) segment is expected to hold a major market share during the forecast period.
The major factors hampering growth of the market include high side effects associated with the medication
Major players operating in the market are Sanofi.,  Pfizer,  F. Hoffman-La Roche AG,  Johnson & Johnson,  AbbVie Inc., Eli Lilly & Company,  Amgen Inc.,  Swedish Orphan Biovitrum AB,  Bristol-Myers Squibb Company,  UCB S.A.,  Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo